Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
J Control Release. 2012 Jul 20;161(2):225-34. doi: 10.1016/j.jconrel.2011.12.014. Epub 2011 Dec 29.
In various systemic disorders, structural changes in the microenvironment of diseased tissues enable both passive and active targeting of therapeutic agents to these tissues. This has led to a number of targeting approaches that enhance the accumulation of drugs in the target tissues, making drug targeting an attractive strategy for the treatment of various diseases. Remarkably, the strategic principles that form the basis of drug targeting are often employed for tumor targeting, while chronic inflammatory diseases appear to draw much less attention. To provide the reader with a general overview of the current status of drug targeting to inflammatory diseases, the passive and active targeting strategies that have been used for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS) are discussed. The last part of this review addresses the dualism of platform technology-oriented ("one for all") and disease-oriented drug targeting research ("all for one"), both of which are key elements of effective drug targeting research.
在各种系统性疾病中，病变组织微环境的结构变化使治疗剂能够被动和主动靶向这些组织。这导致了许多靶向方法，可增强药物在靶组织中的积累，使药物靶向成为治疗各种疾病的一种有吸引力的策略。值得注意的是，构成药物靶向基础的战略原则通常用于肿瘤靶向，而慢性炎症性疾病似乎受到的关注要少得多。为了让读者对炎症性疾病药物靶向的现状有一个总体的了解，本文讨论了用于治疗类风湿关节炎（RA）和多发性硬化症（MS）的被动和主动靶向策略。本综述的最后一部分讨论了以平台技术为导向（“一药多用”）和以疾病为导向的药物靶向研究（“针对一病”）的双重性，这两者都是有效药物靶向研究的关键要素。
